Sartorius CEO Dr Michael Grosse Reports Strong 2025 Performance As Group Revenue Climbs To €3.5 Billion

  Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divi...

February 04, 2026 | Wednesday | Company results
SEQSTER and Praxis Expand Collaboration to Accelerate CNS Clinical Development

Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...

February 04, 2026 | Wednesday | News
insitro Uncovers Novel Peripheral Obesity Target Through AI-Enabled Brown Fat Genetics

AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...

February 04, 2026 | Wednesday | News
AstraZeneca Deepens Weight Management Push With $1.2B AI-Driven Obesity Deal With CSPC

Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...

February 03, 2026 | Tuesday | News
I Peace Establishes Human iPS Cells Derived From NKT Cells, Expanding Immune Cell Therapy Platform

Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...

February 03, 2026 | Tuesday | News
KORU Medical Receives FDA Clearance for FreedomEDGE® Infusion System to Deliver UCB’s RYSTIGGO® in gMG

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the ...

February 02, 2026 | Monday | News
Origami Therapeutics and Ipsen Enter Global Collaboration to Advance Disease-Modifying Therapy for Rare Neurodegenerative Disease

- Ipsen obtains exclusive option to global license a research program for a selective disease-modifying approach to neurodegenerative diseases ...

February 02, 2026 | Monday | News
H.U. Group’s Fujirebio Launches Fully Automated pTau217 CSF Assay for Alzheimer’s Research

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automat...

January 30, 2026 | Friday | News
Tenpoint Therapeutics Raises $235M in Series B Financing and Credit Facility to Support YUVEZZI Launch

Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging...

January 30, 2026 | Friday | News
Takeda CEO Christophe Weber Says FY2025 Is “Pivotal” as Company Raises Outlook Despite VYVANSE Erosion

  Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER); Impact of VYVANSE® Generics is T...

February 02, 2026 | Monday | Company results
Elevar Submits NDA for Lirafugratinib as Second-Line FGFR2-Driven Cholangiocarcinoma Therapy

  Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...

January 30, 2026 | Friday | News
Imviva Biotech’s CTD402 Granted FDA Orphan Drug Designation for Relapsed/Refractory T-ALL/LBL

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...

January 29, 2026 | Thursday | News
Ernexa Therapeutics Selected for Japan Entry Acceleration Program, Joining Elite Group of Global Cell Therapy Innovators

Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...

January 29, 2026 | Thursday | News
Propanc Biopharma Files Fourth Provisional Patent in Two Months, Accelerating Global IP Expansion for Lead Cancer Asset

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...

January 29, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close